Actuate Therapeutics, Inc. (NASDAQ: ACTU) announced that it will present at the H.C. Wainwright 26th Annual Global Investment Conference taking...
Read more
Actuate Therapeutics, Inc., rang the Nasdaq opening bell in celebration of their IPO. This marks the start of an...
Read more
Actuate Therapeutics, Inc. (Nasdaq: ACTU), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high...
Read more
Actuate Therapeutics (ACTU) plans to raise $50 million in an initial public offering on the week of June 24th,...
Read more
Actuate Therapeutics plans to sell nearly 5.56 million shares at between $8 and $10 apiece in its initial public...
Read more
Actuate Therapeutics, a Phase 2 biotech developing in-licensed inhibitor therapies for difficult to treat cancers, filed on Friday with...
Read more
Actuate Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for elraglusib...
Read more
Tempus announced a brand-new multi-omics collaboration with Actuate Therapeutics to support its ongoing Phase 1/2 Study of elraglusib, formerly...
Read more
Actuate Therapeutics and The University of Kansas Cancer Center announced the enrollment of the first patient on a Phase...
Read more
Actuate Therapeutics, Inc. announced that their Phase 2 open-label single arm study of elraglusib (9-ING-41) plus gemcitabine/nab-paclitaxel treatment met...
Read more